Kanpiduo

Indapamide and Candesartan Cilexetil, the active ingredients in Kanpiduo, constitute a combination antihypertensive presented as an oral tablet for systemic administration. The product is indicated for the management of high blood pressure in adult patients, helping to achieve target blood pressure levels when used as part of a comprehensive treatment plan.

GNH USA supplies Kanpiduo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines for cardiovascular care.

Kanpiduo is a combination antihypertensive that targets the renin‑angiotensin system and fluid balance to lower elevated blood pressure.

- Hypertension: reduces systolic and diastolic pressure to achieve guideline‑recommended targets. - Essential hypertension: provides effective control when monotherapy is insufficient. - Primary hypertension: improves overall cardiovascular risk profile. - Isolated systolic hypertension: specifically lowers high systolic readings. - Resistant hypertension: adds further pressure reduction in patients not responding to other agents.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness, especially after standing. - Headache: transient pressure sensation, often resolving with continued therapy. - Increased urination: due to diuretic action, may be more noticeable initially. - Electrolyte imbalance: mild changes in potassium or sodium levels. - Fatigue: general tiredness that may improve over time. - Dry mouth: reduced salivation, usually mild.

Serious or Rare Side Effects: - Severe dehydration: marked fluid loss requiring medical attention. - Hyperkalemia: elevated potassium that can affect heart rhythm. - Acute renal impairment: sudden decline in kidney function. - Angioedema: swelling of face, lips, or throat, potentially life‑threatening. - Hypotension: excessive blood pressure drop causing faintness. - Allergic reaction: rash, itching, or anaphylaxis in rare cases.

Kanpiduo should be used with careful clinical monitoring to ensure safety and efficacy. - Monitor electrolytes: check potassium and sodium levels regularly. - Assess renal function: evaluate creatinine and eGFR before and during therapy. - Avoid in severe hepatic impairment: liver disease may alter drug metabolism. - Use caution in elderly patients: increased sensitivity to blood pressure changes. - Review concomitant antihypertensives: adjust doses to prevent excessive hypotension. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Kanpiduo may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Potassium‑sparing diuretics: risk of dangerous hyperkalemia. - ACE inhibitors: additive blood pressure lowering may cause severe hypotension. - Lithium: increased lithium levels and potential toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: may reduce diuretic effectiveness and affect kidney function. - Antidiabetic agents: blood glucose may drop, requiring dose adjustment. - Beta‑blockers: combined effect can lead to excessive blood pressure reduction.